E76.210 Morquio A mucopolysaccharidoses

Name of the Condition

• Morquio A mucopolysaccharidoses (ICD-10 Code: E76.210)

Summary

Morquio A mucopolysaccharidoses are a rare inherited disorder characterized by the accumulation of glycosaminoglycans (GAGs) due to enzyme deficiencies. This buildup disrupts normal cellular function, leading to progressive multisystem involvement, including skeletal abnormalities, organ enlargement, and neurological impairment. Early recognition and management are important to address complications and slow disease progression.

Causes

The disorder is caused by genetic mutations that impair enzymes responsible for breaking down glycosaminoglycans. These mutations result in the accumulation of undegraded GAGs in cells, tissues, and organs, disrupting normal structure and function. The specific enzyme deficiency determines the type and severity of the condition.

Risk Factors

• Family history of mucopolysaccharidoses or related lysosomal storage disorders.
• Consanguineous relationships (increased risk of recessive inheritance).
• Ethnic or geographic populations with higher carrier rates for specific mutations.

Symptoms

• Skeletal abnormalities, such as short stature, joint stiffness, or dysostosis multiplex.
• Organ enlargement (e.g., hepatosplenomegaly).
• Neurological symptoms, including developmental delay, seizures, or cognitive impairment.
• Coarse facial features, clouded corneas, and respiratory complications.

Diagnosis

Diagnosis involves clinical evaluation, biochemical testing for enzyme deficiencies, and genetic testing to confirm mutations. Imaging studies may assess skeletal abnormalities, while urine tests detect elevated GAG levels. Early diagnosis is critical for timely intervention.

Treatment Options

Treatment focuses on managing symptoms and complications, including enzyme replacement therapy, physical therapy, and surgical interventions for skeletal or organ issues. Multidisciplinary care addresses respiratory, cardiac, and neurological concerns.

Prognosis and Follow-Up

Prognosis varies based on severity and early intervention. Regular follow-up with specialists monitors disease progression, organ function, and treatment response. Lifelong management is often required to address multisystem involvement.

Complications

Complications may include severe skeletal deformities, respiratory insufficiency, cardiac valve disease, hearing loss, and vision impairment. Untreated, the condition can lead to reduced life expectancy.

Lifestyle & Prevention

Supportive care, such as physical therapy and assistive devices, improves mobility. Genetic counseling is recommended for families to understand inheritance risks. No prevention methods exist for inherited forms.

When to Seek Professional Help

Seek care if symptoms like progressive joint stiffness, unexplained organ enlargement, or developmental delays appear. Prompt evaluation is essential for early diagnosis and management.

Tips for Medical Coders

Document clinical findings, diagnostic tests, and treatment plans to support code assignment. Ensure specificity aligns with the ICD-10-CM code E76.210 for Morquio A mucopolysaccharidoses. Include details on enzyme deficiencies or genetic confirmations when available.